Structure Therapeutics Begins Phase 1 Clinical Study Of Oral Small-Molecule Amylin Receptor Agonist ACCG-2671 For Obesity

Structure Therapeutics Inc., a clinical-stage global biopharmaceutical company focused on developing oral small molecule medicines for metabolic diseases, has announced the initiation of a first-in-human Phase 1 clinical trial of ACCG-2671. The company’s research efforts are primarily centered on obesity, and ACCG-2671 is its lead oral small molecule amylin receptor agonist being developed for the treatment of obesity.

ACCG-2671 was created using Structure Therapeutics’ next-generation, structure-based drug discovery platform. The drug is designed to capture the well-established metabolic benefits of amylin biology in an oral, once-daily small molecule form. By developing an oral therapy rather than an injectable one, the company aims to improve treatment scalability, allow easier combination with other obesity medicines, and increase patient access to effective weight management therapies.

Amylin is a hormone known to play an important role in regulating appetite, food intake, and body weight. According to the company, amylin-based treatments are expected to become an important part of future obesity treatment strategies. Using its GPCR-focused drug discovery platform, Structure Therapeutics was able to efficiently advance ACCG-2671 into clinical development, positioning it as the most advanced oral small molecule amylin therapy to enter human testing so far.

Preclinical studies of ACCG-2671 demonstrated strong engagement with the amylin receptor, significant weight loss when used alone, and additional weight loss when combined with a glucagon-like peptide-1 receptor agonist. The drug also showed a favorable safety profile in preclinical testing, along with pharmacokinetic properties that support once-daily oral dosing. Based on these findings, the company believes ACCG-2671 has the potential to serve as a core therapy for obesity, both as a standalone treatment and in combination with other weight loss medications.

The Phase 1 clinical study is designed to assess the safety and tolerability of ACCG-2671, as well as how the drug is absorbed, distributed, and processed in the body. The trial will also evaluate early signs of biological activity related to its mechanism of action. The study will be conducted in both healthy volunteers and individuals with obesity and will include single-ascending dose and multiple-ascending dose cohorts to better understand the appropriate dosing range.

Structure Therapeutics described the initiation of this trial as an important milestone for the company. Following the recent positive Phase 2 results from its ACCESS program evaluating aleniglipron, an oral small molecule GLP-1 receptor agonist, the start of the ACCG-2671 Phase 1 study marks the first clinical advancement from the company’s amylin-focused pipeline. 

Together, these programs highlight the depth of Structure Therapeutics’ metabolic disease portfolio and its ability to translate proven biological pathways into differentiated oral therapies. The company believes these efforts could help expand treatment options, improve long-term outcomes, and increase access for people living with obesity.

Structure Therapeutics Starts Phase 1 Trial of Oral Amylin Drug ACCG-2671